The FDA’s Center for Drug Evaluation and Research (CDER) released a final guidance yesterday on drugs and biologics that contain nanomaterials, noting that the agency has not yet established regulatory definitions of nanomaterials and nanotechnology.
Source: Drug Industry Daily